Physician profile
Sumner Camisa
NPI 1033100540
$9,996.05
in general payments reported to CMS, 2019-2025
46 companies · $1,829 in 2025
The $1,829 reported for 2025 was more than what 92% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $951 · 2020: $1,187 · 2021: $1,694 · 2022: $1,593 · 2023: $1,161 · 2024: $1,580 · 2025: $1,829.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,570.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,570.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $2,071.75 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Lilly USA, LLC | $1,123.76 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $1,090.90 | 2019-2025 | Ozempic, Rybelsus |
| Madrigal Pharmaceuticals | $696.35 | 2024-2025 | Rezdiffra, Resmetirom |
| Boehringer Ingelheim Pharmaceuticals, INC. | $601.30 | 2019-2025 | Jardiance, Ofev, Synjardy |
| Amgen INC. | $559.32 | 2019-2025 | Repatha, Otezla, Evenity |
| Merck Sharp & Dohme LLC | $359.35 | 2019-2025 | Capvaxive, Gardasil 9, Gardasil |
| Bayer Healthcare Pharmaceuticals INC. | $312.22 | 2022-2023 | |
| Abbvie INC. | $303.88 | 2021-2025 | Ubrelvy, Qulipta |
| Teva Pharmaceuticals USA, INC. | $260.64 | 2019-2022 | |
| Glaxosmithkline, LLC. | $249.18 | 2020-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $245.46 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $241.32 | 2020-2022 | |
| Esperion Therapeutics, INC. | $163.81 | 2020-2021 | |
| Dexcom, INC. | $144.61 | 2021-2023 | Dexcom G6 Transmitter |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sumner Camisa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.